Tirzepatide: a quick recap
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It works by mimicking two naturally occurring gut hormones — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) — that regulate insulin secretion, slow gastric emptying, and reduce appetite. This dual-agonist mechanism is what distinguishes tirzepatide from semaglutide, which targets GLP-1 only.
Branded tirzepatide products (Mounjaro for Type 2 diabetes, Zepbound for weight management) are FDA-approved. Compounded tirzepatide from a 503A pharmacy is not FDA-approved and is a distinct product. No efficacy or safety equivalence to branded products should be assumed.
What does glycine do in a compounded tirzepatide formulation?
Glycine is the simplest amino acid and is classified as a pharmaceutical excipient when used in a drug formulation — meaning it is a non-active ingredient that supports the preparation’s physical or chemical properties rather than contributing to the therapeutic effect itself.
In compounded peptide formulations, glycine serves several potential roles:
- Peptide stabilization: Glycine can help maintain the structural integrity of peptides in solution, slowing degradation and extending beyond-use date stability. This is relevant to compounded tirzepatide, which is reconstituted from lyophilized powder or shipped as a liquid solution.
- pH buffering: Glycine has mild buffering properties that can help maintain the solution pH within a range that supports both stability and tolerability at the injection site.
- Injection-site tolerability: Some pharmacies add glycine to reduce stinging or local irritation at the subcutaneous injection site. GLP-1 agonist injections can cause transient discomfort; excipient choices can modulate this.
Glycine itself has an established safety profile when used as a pharmaceutical excipient. Its inclusion in a compounded formulation is common practice across a range of injectable preparations — not unique to tirzepatide.
Glycine and B12 are supporting players in a compounded vial — they shape stability and comfort, not the dual-incretin mechanism doing the work.
What B12 adds to the formulation
Vitamin B12 (as cyanocobalamin or methylcobalamin) is included in some compounded tirzepatide preparations. The rationale varies by pharmacy and clinician, but several considerations are typically cited:
- Energy and fatigue support: Significant caloric restriction accompanying GLP-1 therapy can affect energy levels. B12 plays a role in neurological function, red blood cell production, and energy metabolism. Some clinicians include B12 as a supportive measure during active weight management.
- Dietary intake considerations: Patients on very low-calorie diets or who have reduced food intake may have lower dietary B12 intake, particularly those limiting animal-product consumption. B12 co-administration addresses this gap proactively.
- Subcutaneous administration: B12 delivered subcutaneously bypasses digestive absorption, ensuring reliable bioavailability regardless of gut function or dietary patterns.
B12 is water-soluble and is not associated with toxicity concerns at doses used in injectable preparations. It is widely used as a compounding adjunct across clinical contexts beyond tirzepatide.
What does the evidence show about tirzepatide-glycine-B12 combinations?
The key thing to understand is that the clinical evidence base for tirzepatide is built on the branded product, not on compounded formulations with glycine and B12. The landmark SURMOUNT-1 trial and the SURPASS series that established tirzepatide’s weight management and metabolic benefits used Eli Lilly’s formulation of tirzepatide — not a compounded version with additional excipients.
There are no published head-to-head trials comparing tirzepatide-glycine-B12 compounded formulations to tirzepatide alone, or to branded Mounjaro or Zepbound. The addition of glycine and B12 is a compounding pharmacy practice supported by pharmacokinetic and clinical reasoning, not by dedicated randomized controlled trials of the combination.
What this means practically: you should not assume that a compounded tirzepatide formulation with glycine and B12 is therapeutically equivalent to, better than, or inferior to branded tirzepatide. The honest answer is that direct comparison data does not exist.
Questions to ask your clinician
If you’re starting or considering compounded tirzepatide, here are practical questions worth asking:
- What is the exact formulation — tirzepatide concentration, glycine amount, B12 form and dose?
- What is the beyond-use date for the reconstituted solution, and how should it be stored?
- Is the active pharmaceutical ingredient (API) sourced domestically from a licensed supplier?
- Does the pharmacy have a Certificate of Analysis (CoA) for each batch?
- What is the starting dose and titration schedule?
- What monitoring — labs, check-ins — is included?
A clinician who cannot or will not answer these questions is a signal to look for a different provider. Quality in compounded peptide therapy lives in the details of the pharmacy and the oversight.
Frequently asked questions
Why is glycine added to some compounded tirzepatide formulations?
Glycine is an amino acid used as an excipient — a non-active ingredient that affects stability, solubility, or tolerability of the formulation. In some compounded tirzepatide preparations, glycine is included to help stabilize the peptide in solution and may buffer injection-site discomfort. The specific rationale varies by pharmacy; ask your pharmacy what role each excipient plays in your formulation.
What does B12 do in a tirzepatide formulation?
Vitamin B12 (cyanocobalamin or methylcobalamin) is added to some compounded tirzepatide preparations. Some clinicians and pharmacies include it to support energy, reduce fatigue associated with caloric restriction, or address potential B12 depletion patterns in patients following significant dietary changes. B12 is water-soluble and generally well-tolerated when co-administered subcutaneously.
Does tirzepatide with glycine and B12 work better than tirzepatide alone?
There are no published clinical trials directly comparing compounded tirzepatide-glycine-B12 formulations to tirzepatide alone. The clinical evidence for tirzepatide comes from trials of the branded product Mounjaro/Zepbound. Whether excipient additions materially affect outcomes in compounded formulations is not established by controlled data.
Is tirzepatide with glycine and B12 FDA-approved?
No. Compounded tirzepatide formulations — with or without glycine and B12 — are not FDA-approved. They are prepared by licensed 503A compounding pharmacies under a clinician prescription for individual patients. This is different from the FDA-approved branded products Mounjaro and Zepbound.
Can I request a specific tirzepatide formulation?
Your prescribing clinician and compounding pharmacy determine the formulation. Discuss your preferences and any concerns with your clinician before starting — they can review which excipients are included and why.
The PepScribe approach
PepScribe works with licensed 503A compounding pharmacies in the USA. Every formulation a clinician prescribes through our platform comes from a US-licensed pharmacy. No hidden overseas supply chain. If you want to understand the specifics of any formulation, your clinician will walk you through it at intake.
More on our tirzepatide program is on the tirzepatide overview page.